Potential role of lampalizumab for treatment of&nbsp;geographic atrophy | Zendy

Diana Do | Zendy; William Rhoades | Zendy; Drew Dickson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential role of lampalizumab for treatment of geographic atrophy

Author(s) -

Diana Do,

William Rhoades,

Drew Dickson

Publication year - 2015

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s59725

Subject(s) - geographic atrophy , medicine , macular degeneration , atrophy , clinical trial , ophthalmology , degeneration (medical) , investigational drugs

The purpose of this article is to review the pathways underlying age-related macular degeneration and potential therapeutic targets, focusing on the complement pathway and the recent MAHALO Phase II trial of the investigational drug lampalizumab. This trial was the first to have shown positive results for the treatment of geographic atrophy in age-related macular degeneration. It has potential as a future treatment, and is currently undergoing a Phase III trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research